9004-61-9

Usage

InChI:InChI=1/C28H44N2O23/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45)/t7-,8-,9-,10-,11-,12-,13+,14?,15-,16-,17-,18-,19?,20+,21+,22?,25?,26+,27+,28-/m1/s1

Upstream product

• 9067-32-7 sodium hyaluronate 

Downstream Products

• 90-76-6 2-deoxy-2-amino glucose 
• 6556-12-3 D-glucuronic acid 
• 9067-32-7 sodium hyaluronate 

Relevant academic research and scientific papers

Peroxynitrite (ONOO-) generation from the HA-TPP@NORM nanoparticles based on synergistic interactions between nitric oxide and photodynamic therapies for elevating anticancer efficiency

Due to biological safety and negligible toxicity, nitric oxide (NO) therapy has gained increasing interest in the field of cancer therapy during the past few years. However, individual NO cancer therapy normally exhibited limited therapeutic efficiency. In order to acquire satisfactory therapeutic outcomes, the NO therapy is usually combined with other therapeutic treatments, mostly chemotherapy. Herein, we constructed HA-TPP@NORM nanoparticles based on the co-assembly of an NO donor (NORM) and tetraphenylporphyrin (TPP)-modified hyaluronic acid, which can efficiently generate a highly biocidal molecule of peroxynitrite (ONOO-) via the synergistic interactions of the nitric oxide (NO) therapy and photodynamic therapy (PDT) to enhance the cancer therapeutic efficiency. In addition, MTT results exhibited that without light irradiation, the HA-TPP@NORM nanoparticles have favourable biocompatibility with the cell viability above 95% at the maximum TPP concentration (20 μg mL-1). Under simultaneous irradiation with 365 nm and 650 nm light, ONOO- can be efficiently produced in cancer cells via the direct coupling reaction of the generated NO and superoxide anion radical (O2-), which significantly enhanced the anticancer effect, when compared with individual NO therapy or PDT therapy. Therefore, the HA-TPP@NORM nanoparticles may provide a new insight into the design of efficiently NO-related cancer therapeutic systems.

COMPOSITION COMPRISING HYALURONIC ACID AND/OR ITS SALTS FOR TREATMENT OF ATOPIC DERMATITIS

Provided is a composition for prevention and treatment of atopic dermatitis, comprising hyaluronic acid and/or a salt thereof, and preferably resveratrol. The composition has therapeutic effects on amelioration and treatment of atopic dermatitis which is an allergic disease.

PHARMACEUTICAL FORMULATIONS

The present invention relates to salts of a biodegradable polymeric sugars comprising acidic groups and a pharmaceutically active agent comprising one or more basic groups, and to pharmaceutical formulations of said salts adapted for administration by inhalation.Λa présente invention a trait à des sels d''un sucre polymérique biodégradable comportant des groupes acides et un agent pharmaceutiquement actif comportant un ou des groupes basiques, et à des formulations pharmaceutiques desdits sels adaptées pour une administration par inhalation.

Method for producing alkyl-esterified glycosaminoglycan

A method for producing an alkyl-esterified glycosaminoglycan, which comprises the step of allowing a trialkylsilyldiazoalkane to act on a glycosaminoglycan to perform alkyl-esterification of carboxyl groups of the glycosaminoglycan, and an alkyl-esterified glycosaminoglycan having a property that it is not substantially degraded by a glycosaminoglycan degrading enzyme such as hyaluronidase are provided.

Cross-linked hyaluronic acids and medical uses thereof

Cross-linked hyaluronic acids produced by the reaction of the carboxylic acid groups of hyaluronic acid and a polyamine and the sulfated and hemisuccinylated derivates thereof. The cross-linked hyaluronic acids are useful for various pharmaceutical and medical purposes.